Skip to main content
Nitin Jain on Muck Rack

Nitin Jain

As seen in: Medium, Daily Mail, Forbes, MSN India, Nature, The Times of India, Wiley Online Library, British Journal of Sports Medicine, Educational Studies, MDPI and

Get in touch with Nitin

Contact Nitin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage

|
By Roberta S. Azevedo, Elias Jabbour, Nitin Jain, Fadi Haddad, Partow Kebriaei, Issa Khouri, Elizabeth J. Shpall, Richard Champlin, Omer S. Karrar, Jayastu Senapati, Eitan Kugler, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian, Nicholas Short, Manuel Maroun
| Nature Verified
Abstract The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with B-cell–directed immunotherapies remains controversial. We analyzed 172 adults treated in first salvage with blinatumomab and/or inotuzumab ozogamicin (InO)–based regimens to determine prognostic factors and benefit from allo-HSCT after achieving remission.
Open in Who Shared Issue with article?

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety

|
By Atharva Karulkar, Hasmukh Jain, Neeraj Sidharthan, Dinesh Bhurani, Sameer Melinkeri, Pavan Kumar Boyella, Prashant Mehta, Esha Kaul, Sanket R. Shah, Chandran Nair, Rahul Bhargava, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty, Hari Menon, Devanshi Kalra, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar, Jayachandran P. K, Rakesh Reddy Boya, Ram Abhinav, Smrithi Ravikumar, Jayashree Thorat
| Nature Verified
Abstract Talicabtagene autoleucel (tali-cel) is the first humanized CD19-directed CAR-T cell therapy approved in India for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Here, we integrated clinical and manufacturing operations through a centralized coordination unit (CCU) and evaluated tali-cel implementation.
Open in Who Shared Issue with article?

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia

|
By Elias Jabbour, Caitlin R Rausch, Hannah Goulart, Nitin Jain, Farhad Ravandi, Abhishek Maiti, Yesid Reyes Alvarado, Jan Burger, Musa Yilmaz, Issa Khouri, Partow Kebriaei, Jeffrey L. Jorgensen, A. Wang, Xuemei Wang, Rebecca Garris, Nicholas Short, Hagop Kantarjian, Ejiroghene Mayor
| Nature Verified
Abstract Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL).
Open in Who Shared Issue with article?
See all 437 licensed articles (468 Total)